trending Market Intelligence /marketintelligence/en/news-insights/trending/GZ_SXQlKVSJzWd2gBHdKRg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

BIO Asia: Sinorda aims to go public in 2 years; to close A round financing in H1

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


BIO Asia: Sinorda aims to go public in 2 years; to close A round financing in H1

Sinorda Biomedicine Ltd. aims to go public in 2020 or 2021, Chairman Hu Pingsheng told S&P Global Market Intelligence on the sidelines of the 2019 BIO Asia International conference in Tokyo.

Hu said the company is in talks with investment banks and will prioritize listing in Hong Kong and on the new Shanghai trading board.

The Hong Kong stock exchange in April last year eased listing rules to enable pre-revenue biotech companies go public. The Shanghai Stock Exchange will follow suit in a bid to attract biotech startups with similar relaxed rules.

Hangzhou-based Sinorda has more than five drugs under clinical study, according to Hu. The company completed a phase 1 study in Europe for one of its main products for gastric acid-related diseases, X842. Sinorda expects to finish a phase 1 for the drug in China soon, and a phase 2 study in 2020.

Sinorda is also in talks to in-license anti-inflammatory drugs.

Further, Hu said the company plans to complete an A round financing of about US$200 million to US$300 million in April or May, and will start a new round of financing by the end of 2019.